CHARMD

Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database


    • TOP

    Human betaherpesvirus 5

    Mutations

    Mutant Gene Antiviral EC50 ratio Phenotype Assay Reference
    P10L UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    L11P UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    P12L UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    E22STOP UL27 Maribavir 2.00 Low level resistance Details Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    A58T UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    D81N UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    A83V UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    A84P UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    A84V UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    K90R UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    H97R UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    L133I UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    A134T UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    W153R UL27 Maribavir 1.70 No resistance Details Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    L193F UL27 Maribavir 2.60 Low level resistance Details Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    C218del UL27 Maribavir 2.50 Low level resistance Details Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    E229D UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    R233S UL27 Maribavir Details Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. (Jul 2004)
    R233S UL27 Maribavir 0.20 Possible hypersensitivity, no resistance Details Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. (Sep 2018)
    A269T UL27 Maribavir 2.00 Low level resistance Details Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    N289D UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    D294N UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    D294G UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    H297Y UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    D298G UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    N300G UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    301-311del UL27 Maribavir 3.10 Intermediate level resistance Details Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    P307L UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    V310A UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    H313Y UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    L335P UL27 Maribavir 23.00 High level resistance Details Resistance of human cytomegalovirus to D- and L-ribosyl benzimidazoles as a tool to identify potential targets for antiviral drugs. (May-Aug 2003)
    G344D UL27 Maribavir 0.90 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    D351N UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    V353E UL27 Maribavir 2.10 Low level resistance Details Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    W362R UL27 Maribavir 1.90 No resistance Details Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. (Jul 2004)
    W362STOP UL27 Maribavir 2.20 Low level resistance Details Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    S363W UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    I367V UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    G421E UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    L426F UL27 Maribavir 2.20 Low level resistance Details Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    R465C UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    T519A UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    A520V UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    R531Q UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    H557Q UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    A558V UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    A565T UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    P571T UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    H606Y UL27 Natural polymorphism Details Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009)
    A4T UL51 Natural polymorphism Details First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    D12E UL51 Letermovir 1.40 No resistance Details First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    G16A UL51 Natural polymorphism Details First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    E17A UL51 Natural polymorphism Details First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    E17del UL51 Letermovir 1.30 No resistance Details First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    Q23K UL51 Natural polymorphism Details First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    D24G UL51 Natural polymorphism Details First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    S28F UL51 Natural polymorphism Details First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    E39D UL51 Natural polymorphism Details First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    D40N UL51 Natural polymorphism Details First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    E42G UL51 Natural polymorphism Details First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    G56D UL51 Natural polymorphism Details First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    G61D UL51 Natural polymorphism Details First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    L70I UL51 Natural polymorphism Details First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    P91S UL51 Letermovir 2.10 Low level resistance Details A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
    A95V UL51 Letermovir 13.80 High level resistance Details First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    V113L UL51 Letermovir 1.50 No resistance Details First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    S153P UL51 Natural polymorphism Details First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
    N4H UL54 Natural polymorphism Details
    N4Y UL54 Natural polymorphism Details
    S8N UL54 Natural polymorphism Details
    S8T UL54 Natural polymorphism Details
    A15S UL54 Natural polymorphism Details
    A17P UL54 Natural polymorphism Details
    R21C UL54 Natural polymorphism Details
    S24L UL54 Natural polymorphism Details
    S32P UL54 Natural polymorphism Details
    V95E UL54 Natural polymorphism Details
    H142Y UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G143S UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    D163H UL54 Natural polymorphism Details
    Q229K UL54 Ganciclovir 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q229K UL54 Cidofovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q229K UL54 Foscarnet 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E235G UL54 Non-viable Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    T242K UL54 Natural polymorphism Details
    D247N UL54 Ganciclovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D247N UL54 Cidofovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D247N UL54 Foscarnet 1.30 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    C256S UL54 Natural polymorphism Details
    C256L UL54 Natural polymorphism Details
    D262N UL54 Ganciclovir 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D262N UL54 Cidofovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D262N UL54 Foscarnet 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    N267Y UL54 Natural polymorphism Details
    A269V UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D271A UL54 Ganciclovir 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D271A UL54 Cidofovir 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D271A UL54 Foscarnet 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D284E UL54 Foscarnet 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D288N UL54 Ganciclovir 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D288N UL54 Cidofovir 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D288N UL54 Foscarnet 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S290R UL54 Cidofovir 1.30 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R UL54 Cidofovir 1.40 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R UL54 Foscarnet 2.20 Low level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R UL54 Foscarnet 2.30 Low level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R UL54 Ganciclovir 1.50 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R UL54 Ganciclovir 1.70 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    D301N UL54 Ganciclovir 2.60 Low level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    D301N UL54 Cidofovir 3.00 Intermediate level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    D301N UL54 Foscarnet 0.50 No resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E303G UL54 Brincidofovir 11.00 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303G UL54 Cidofovir 20.00 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303G UL54 Ganciclovir 7.30 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303G UL54 Foscarnet 0.80 No resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303D UL54 Brincidofovir 9.70 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303D UL54 Cidofovir 16.00 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303D UL54 Ganciclovir 6.30 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303D UL54 Foscarnet 0.80 No resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    A336T UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I341T UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    N345S UL54 Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G347D UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    T351A UL54 Natural polymorphism Details
    V355A UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    F357I UL54 Natural polymorphism Details
    P375L UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Y380C UL54 Non-viable Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L394F UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F396L UL54 Ganciclovir 1.40 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F396L UL54 Cidofovir 1.50 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F396L UL54 Foscarnet 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    N408D UL54 Ganciclovir 4.90 Intermediate level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    N408H UL54 Ganciclovir 2.00 Low level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    N408H UL54 Cidofovir 3.30 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    N408D UL54 Cidofovir 5.60 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    N408D UL54 Foscarnet 1.30 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    N408H UL54 Foscarnet 3.00 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    N408K UL54 Ganciclovir 4.20 Intermediate level resistance Details Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. (Jan 2007)
    N408K UL54 Cidofovir 21.00 High level resistance Details Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. (Jan 2007)
    N408K UL54 Foscarnet 0.70 No resistance Details Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. (Jan 2007)
    N408K UL54 Brincidofovir 11.00 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    N408S UL54 Ganciclovir 3.10 Intermediate level resistance Details Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    N408S UL54 Cidofovir 7.50 High level resistance Details Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    N408S UL54 Foscarnet 1.00 No resistance Details Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    N410K UL54 Ganciclovir 2.90 Low level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    N410K UL54 Cidofovir 3.00 Intermediate level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    N410K UL54 Foscarnet 0.80 No resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    F412C UL54 Ganciclovir 4.20 Intermediate level resistance Details Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    F412C UL54 Cidofovir 18.00 High level resistance Details Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    F412C UL54 Foscarnet 1.20 No resistance Details Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    F412L UL54 Ganciclovir 4.60 Intermediate level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412L UL54 Cidofovir 9.40 High level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412L UL54 Foscarnet 1.10 No resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412S UL54 Ganciclovir 5.30 High level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412S UL54 Cidofovir 13.00 High level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412S UL54 Foscarnet 0.80 No resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412V UL54 Ganciclovir 4.30 Intermediate level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    F412V UL54 Cidofovir 15.50 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    F412V UL54 Foscarnet 1.10 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    D413A UL54 Ganciclovir 6.50 High level resistance Details Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    D413A UL54 Cidofovir 11.00 High level resistance Details Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    D413A UL54 Foscarnet 0.80 No resistance Details Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    D413E UL54 Ganciclovir 4.80 Intermediate level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    D413E UL54 Cidofovir 4.30 Intermediate level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    D413E UL54 Foscarnet 0.80 No resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    D413N UL54 Ganciclovir 3.80 Intermediate level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    D413N UL54 Cidofovir 10.00 High level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    D413N UL54 Foscarnet 1.00 No resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    D413del UL54 Brincidofovir 5.20 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413del UL54 Cidofovir 5.80 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413del UL54 Ganciclovir 3.80 Intermediate level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413del UL54 Foscarnet 1.30 No resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413Y UL54 Brincidofovir 6.00 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413Y UL54 Cidofovir 9.30 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413Y UL54 Ganciclovir 4.40 Intermediate level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413Y UL54 Foscarnet 1.00 No resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    L424V UL54 Ganciclovir 1.30 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L424V UL54 Cidofovir 1.30 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L424V UL54 Foscarnet 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    K426R UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    K426E UL54 Cidofovir 1.00 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E UL54 Cidofovir 0.90 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E UL54 Foscarnet 1.10 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E UL54 Foscarnet 0.90 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E UL54 Ganciclovir 1.00 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E UL54 Ganciclovir 1.10 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    G441S UL54 Natural polymorphism Details Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    V450G UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F460L UL54 Ganciclovir 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F460L UL54 Cidofovir 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F460L UL54 Foscarnet 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F460S UL54 Natural polymorphism Details Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    S464F UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    H465Y UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    N467S UL54 Natural polymorphism Details
    A469T UL54 Natural polymorphism Details
    A473V UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V476G UL54 Ganciclovir 0.80 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V476G UL54 Cidofovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V476G UL54 Foscarnet 0.40 Possible hypersensitivity, no resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V482G UL54 Non-viable Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V483A UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P488R UL54 Ganciclovir 3.50 Intermediate level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    P488R UL54 Cidofovir 7.90 High level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    P488R UL54 Foscarnet 0.60 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    A492D UL54 Ganciclovir 1.35 No resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    A492D UL54 Cidofovir 1.36 No resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    A492D UL54 Foscarnet 1.45 No resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    N495K UL54 Ganciclovir 1.10 No resistance Details A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. ( 2006)
    N495K UL54 Cidofovir 1.10 No resistance Details A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. ( 2006)
    N495K UL54 Foscarnet 3.40 Intermediate level resistance Details A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. ( 2006)
    N495K UL54 Cidofovir 1.20 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K UL54 Cidofovir 1.00 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K UL54 Foscarnet 2.50 Low level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K UL54 Foscarnet 2.60 Low level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K UL54 Ganciclovir 1.30 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K UL54 Ganciclovir 1.40 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    P497S UL54 Cidofovir 2.40 Low level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    P497S UL54 Foscarnet 0.80 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    P497S UL54 Ganciclovir 1.90 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    N498S UL54 Cidofovir 1.80 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    N498S UL54 Foscarnet 1.70 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    N498S UL54 Ganciclovir 1.70 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    K500N UL54 Ganciclovir 3.20 Intermediate level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    K500N UL54 Cidofovir 3.00 Intermediate level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    K500N UL54 Foscarnet 1.20 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L501F UL54 Ganciclovir 2.60 Low level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L501F UL54 Cidofovir 3.80 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L501F UL54 Foscarnet 1.30 No resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L501I UL54 Ganciclovir 6.00 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    L501I UL54 Cidofovir 9.10 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    L501I UL54 Foscarnet 1.40 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    T503A UL54 Ganciclovir 3.10 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    T503A UL54 Cidofovir 3.70 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    T503A UL54 Foscarnet 1.50 No resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    T503I UL54 Ganciclovir 2.90 Low level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    T503I UL54 Cidofovir 6.10 High level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    T503I UL54 Foscarnet 0.50 No resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    A505V UL54 Ganciclovir 1.80 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A505V UL54 Cidofovir 2.00 Low level resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A505V UL54 Foscarnet 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    R512C UL54 Natural polymorphism Details Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    K513Q UL54 Ganciclovir 6.60 High level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    K513Q UL54 Cidofovir 18.00 High level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    K513Q UL54 Foscarnet 1.00 No resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    K513E UL54 Ganciclovir 5.00 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    K513E UL54 Cidofovir 9.10 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    K513E UL54 Foscarnet 1.40 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    K513N UL54 Ganciclovir 6.00 High level resistance Details A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. (Sep 1998)
    K513N UL54 Cidofovir 12.50 High level resistance Details A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. (Sep 1998)
    K513N UL54 Foscarnet 1.50 No resistance Details A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. (Sep 1998)
    K513R UL54 Ganciclovir 3.70 Intermediate level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    K513R UL54 Cidofovir 10.00 High level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    K513R UL54 Foscarnet 1.10 No resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    D515G UL54 Natural polymorphism Details
    D515E UL54 Ganciclovir 2.70 Low level resistance Details Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. (Nov 2000)
    D515E UL54 Cidofovir 1.60 No resistance Details Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. (Nov 2000)
    D515E UL54 Foscarnet 4.60 Intermediate level resistance Details Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. (Nov 2000)
    D515E UL54 Cidofovir 1.10 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D515E UL54 Foscarnet 0.90 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D515E UL54 Ganciclovir 1.00 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D515Y UL54 Ganciclovir 6.20 High level resistance Details Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. (May 2016)
    D515Y UL54 Cidofovir 0.87 No resistance Details Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. (May 2016)
    D515Y UL54 Foscarnet 4.70 Intermediate level resistance Details Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. (May 2016)
    D515Y UL54 Cidofovir 2.60 Low level resistance Details Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    D515Y UL54 Foscarnet 1.10 No resistance Details Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    D515Y UL54 Ganciclovir 3.20 Intermediate level resistance Details Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    L516R UL54 Ganciclovir 2.10 Low level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    L516R UL54 Cidofovir 5.10 High level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    L516R UL54 Foscarnet 0.80 No resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    L516W UL54 Ganciclovir 4.20 Intermediate level resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    L516W UL54 Cidofovir 8.49 High level resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    L516W UL54 Foscarnet 1.22 No resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    Y518C UL54 Natural polymorphism Details
    I521T UL54 Ganciclovir 2.10 Low level resistance Details Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    I521T UL54 Cidofovir 5.10 High level resistance Details Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    I521T UL54 Foscarnet 0.80 No resistance Details Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522L UL54 Natural polymorphism Details Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522T UL54 Ganciclovir 2.10 Low level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    P522T UL54 Cidofovir 2.00 Low level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    P522T UL54 Foscarnet 1.40 No resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    P522A UL54 Ganciclovir 3.00 Intermediate level resistance Details Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522A UL54 Cidofovir 4.10 Intermediate level resistance Details Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522A UL54 Foscarnet 1.00 No resistance Details Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522S UL54 Ganciclovir 3.10 Intermediate level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    P522S UL54 Cidofovir 3.60 Intermediate level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    P522S UL54 Foscarnet 1.10 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    C524del UL54 Ganciclovir 3.50 Intermediate level resistance Details Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    C524del UL54 Cidofovir 9.70 High level resistance Details Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    C524del UL54 Foscarnet 1.10 No resistance Details Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    V526L UL54 Ganciclovir 5.50 High level resistance Details Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. (Nov 2014)
    V526L UL54 Cidofovir 2.50 Low level resistance Details Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. (Nov 2014)
    V526L UL54 Foscarnet 1.80 No resistance Details Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. (Nov 2014)
    C539G UL54 Ganciclovir 3.10 Intermediate level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    C539G UL54 Cidofovir 4.40 Intermediate level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    C539G UL54 Foscarnet 1.00 No resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    C539R UL54 Ganciclovir 3.20 Intermediate level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    C539R UL54 Cidofovir 13.30 High level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    C539R UL54 Foscarnet 0.70 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    Q541P UL54 Natural polymorphism Details
    D542E UL54 Ganciclovir 1.50 No resistance Details Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. (Jul 2013)
    D542E UL54 Cidofovir 12.00 High level resistance Details Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. (Jul 2013)
    D542E UL54 Foscarnet 1.70 No resistance Details Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. (Jul 2013)
    D542E UL54 Cidofovir 13.00 High level resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D542E UL54 Foscarnet 0.50 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D542E UL54 Ganciclovir 3.50 Intermediate level resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A543S UL54 Ganciclovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A543S UL54 Cidofovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A543S UL54 Foscarnet 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A543V UL54 Cidofovir 10.00 High level resistance Details Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    A543V UL54 Cidofovir 3.20 Intermediate level resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A543V UL54 Foscarnet 0.70 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A543V UL54 Ganciclovir 2.10 Low level resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    L545F UL54 Ganciclovir 4.00 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L545F UL54 Cidofovir 11.00 High level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L545F UL54 Foscarnet 1.20 No resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L545S UL54 Ganciclovir 3.50 Intermediate level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    L545S UL54 Cidofovir 9.10 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    L545S UL54 Foscarnet 1.20 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    L545W UL54 Ganciclovir 4.90 Intermediate level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    L545W UL54 Cidofovir 6.30 High level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    L545W UL54 Foscarnet 1.30 No resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    T552N UL54 Ganciclovir 1.90 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    T552N UL54 Cidofovir 1.20 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    T552N UL54 Foscarnet 2.60 Low level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    T552N UL54 Cidofovir 1.00 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N UL54 Cidofovir 1.70 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N UL54 Foscarnet 2.50 Low level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N UL54 Foscarnet 3.10 Intermediate level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N UL54 Ganciclovir 1.80 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N UL54 Ganciclovir 2.60 Low level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552S UL54 Foscarnet 0.50 No resistance Details Immune restoration therapy for multidrug-resistant CMV disease in an allogenic stem cell transplant recipient. (May 2022)
    T552S UL54 Ganciclovir 3.00 Intermediate level resistance Details Immune restoration therapy for multidrug-resistant CMV disease in an allogenic stem cell transplant recipient. (May 2022)
    T552S UL54 Cidofovir 2.70 Low level resistance Details Immune restoration therapy for multidrug-resistant CMV disease in an allogenic stem cell transplant recipient. (May 2022)
    L565V UL54 Cidofovir 1.60 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    L565V UL54 Foscarnet 3.70 Intermediate level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    L565V UL54 Ganciclovir 1.80 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    Q578H UL54 Ganciclovir 3.30 Intermediate level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    Q578H UL54 Cidofovir 2.30 Low level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    Q578H UL54 Foscarnet 4.50 Intermediate level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    Q578L UL54 Ganciclovir 1.90 No resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    Q578L UL54 Cidofovir 0.80 No resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    Q578L UL54 Foscarnet 3.00 Intermediate level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    R581H UL54 Non-viable Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S585A UL54 Ganciclovir 1.50 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    S585A UL54 Cidofovir 1.40 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    S585A UL54 Foscarnet 2.70 Low level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    D588E UL54 Ganciclovir 1.30 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    D588E UL54 Cidofovir 1.10 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    D588E UL54 Foscarnet 2.30 Low level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    D588N UL54 Ganciclovir 3.80 Intermediate level resistance Details How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    D588N UL54 Cidofovir 2.70 Low level resistance Details How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    D588N UL54 Foscarnet 3.20-9.00 Range of values between Intermediate level resistance and High level resistance Details How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    C590F UL54 Ganciclovir 1.60 No resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    C590F UL54 Cidofovir 1.60 No resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    C590F UL54 Foscarnet 2.30 Low level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    D594N UL54 Cidofovir 1.00 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    D594N UL54 Foscarnet 1.00 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    D594N UL54 Ganciclovir 1.00 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    F595I UL54 Ganciclovir 1.30 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    F595I UL54 Cidofovir 1.20 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    F595I UL54 Foscarnet 2.00 Low level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    G604S UL54 Natural polymorphism Details
    S612N UL54 Natural polymorphism Details
    P617S UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I622L UL54 Natural polymorphism Details
    I622L UL54 Natural polymorphism Details Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. (Apr 2010)
    A626V UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    P628A UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P628L UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G629S UL54 Natural polymorphism Details
    A631G UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S633F UL54 Natural polymorphism Details
    V634A UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    M640R UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A647S UL54 Natural polymorphism Details
    S651E UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G653S UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V654G UL54 Ganciclovir 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V654G UL54 Cidofovir 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V654G UL54 Foscarnet 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S655L UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S660G UL54 Ganciclovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S660G UL54 Cidofovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S660G UL54 Foscarnet 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S660N UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S663N UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G667N UL54 Ganciclovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G667N UL54 Cidofovir 0.80 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G667N UL54 Foscarnet 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F669L UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S676G UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G678S UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    V681del UL54 Natural polymorphism Details
    N685S UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    H686Y UL54 Natural polymorphism Details
    A688V UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G689R UL54 Natural polymorphism Details
    T691A UL54 Natural polymorphism Details
    T691A UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    T691S UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692G UL54 Ganciclovir 0.80 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692G UL54 Cidofovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692G UL54 Foscarnet 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692F UL54 Natural polymorphism Details
    A692V UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692S UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A693T UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S695T UL54 Natural polymorphism Details
    Q697H UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    T700A UL54 Ganciclovir 0.90 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    T700A UL54 Cidofovir 1.50 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    T700A UL54 Foscarnet 4.70 Intermediate level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    V715A UL54 Ganciclovir 1.77 No resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    V715A UL54 Cidofovir 0.47 Possible hypersensitivity, no resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    V715A UL54 Foscarnet 2.50 Low level resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    V715M UL54 Ganciclovir 1.00 No resistance Details Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. (Mar 1996)
    V715M UL54 Cidofovir 1.10 No resistance Details Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. (Mar 1996)
    V715M UL54 Foscarnet 5.50 High level resistance Details Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. (Mar 1996)
    F718L UL54 Non-viable Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F718S UL54 Non-viable Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I722V UL54 Natural polymorphism Details
    I726T UL54 Ganciclovir 2.00 Low level resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726T UL54 Cidofovir 1.70 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726T UL54 Foscarnet 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726V UL54 Ganciclovir 1.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726V UL54 Cidofovir 1.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726V UL54 Foscarnet 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L737M UL54 Natural polymorphism Details
    E756D UL54 Ganciclovir 1.20 No resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756D UL54 Cidofovir 0.70 No resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756D UL54 Foscarnet 3.40 Intermediate level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756K UL54 Ganciclovir 2.50 Low level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756K UL54 Cidofovir 2.20 Low level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756K UL54 Foscarnet >8.00 At least High level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756Q UL54 Ganciclovir 1.70 No resistance Details Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    E756Q UL54 Cidofovir 1.00 No resistance Details Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    E756Q UL54 Foscarnet 4.30 Intermediate level resistance Details Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    V759M UL54 Natural polymorphism Details
    L773V UL54 Ganciclovir 3.00 Intermediate level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    L773V UL54 Cidofovir 2.50 Low level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    L773V UL54 Foscarnet 4.40 Intermediate level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    L776M UL54 Ganciclovir 2.50 Low level resistance Details Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. (May 2008)
    L776M UL54 Cidofovir 1.00 No resistance Details Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. (May 2008)
    L776M UL54 Foscarnet 3.50 Intermediate level resistance Details Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. (May 2008)
    V781I UL54 Ganciclovir 1.00-4.00 Range of values between No resistance and Intermediate level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    V781I UL54 Cidofovir 1.20 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    V781I UL54 Foscarnet 4.00-5.20 Range of values between Intermediate level resistance and High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    Q783R UL54 Cidofovir 0.90 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    Q783R UL54 Foscarnet 1.70 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    Q783R UL54 Ganciclovir 1.80 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    Q783R UL54 Ganciclovir 1.30 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A786P UL54 Natural polymorphism Details
    A786V UL54 Cidofovir 1.00 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A786V UL54 Foscarnet 1.10 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A786V UL54 Ganciclovir 1.00 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    V787A UL54 Ganciclovir 2.50 Low level resistance Details Rapid detection of human cytomegalovirus UL97 and UL54 mutations for antiviral resistance in clinical specimens. (May 2013)
    V787A UL54 Cidofovir Details Rapid detection of human cytomegalovirus UL97 and UL54 mutations for antiviral resistance in clinical specimens. (May 2013)
    V787A UL54 Foscarnet 3.50 Intermediate level resistance Details Rapid detection of human cytomegalovirus UL97 and UL54 mutations for antiviral resistance in clinical specimens. (May 2013)
    V787E UL54 Ganciclovir 8.60 High level resistance Details Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. (Sep 2019)
    V787E UL54 Cidofovir 2.90 Low level resistance Details Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. (Sep 2019)
    V787E UL54 Foscarnet 3.40 Intermediate level resistance Details Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. (Sep 2019)
    V787L UL54 Ganciclovir 2.40 Low level resistance Details Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    V787L UL54 Cidofovir 1.00 No resistance Details Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    V787L UL54 Foscarnet 4.10 Intermediate level resistance Details Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    R792S UL54 Natural polymorphism Details
    E793V UL54 Ganciclovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E793V UL54 Cidofovir 0.70 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E793V UL54 Foscarnet 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795P UL54 Ganciclovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795P UL54 Cidofovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795P UL54 Foscarnet 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795R UL54 Ganciclovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795R UL54 Cidofovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795R UL54 Foscarnet 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V798A UL54 Cidofovir 1.00 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V798A UL54 Cidofovir 1.10 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V798A UL54 Foscarnet 1.70 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V798A UL54 Foscarnet 1.80 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V798A UL54 Ganciclovir 1.50 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    R800C UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L802M UL54 Ganciclovir 1.10-3.50 Range of values between No resistance and Intermediate level resistance Details Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    L802M UL54 Cidofovir 0.90-1.80 Range of values of No resistance Details Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    L802M UL54 Foscarnet 3.20-10.80 Range of values between Intermediate level resistance and High level resistance Details Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    L802V UL54 Ganciclovir 1.80 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L802V UL54 Cidofovir 1.10 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L802V UL54 Foscarnet 0.90 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    K805Q UL54 Ganciclovir 1.00 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    K805Q UL54 Cidofovir 2.20 Low level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    K805Q UL54 Foscarnet 0.18 Possible hypersensitivity, no resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    A809V UL54 Ganciclovir 2.60 Low level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    A809V UL54 Cidofovir 1.70 No resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    A809V UL54 Foscarnet 6.30 High level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    A809V UL54 Foscarnet 3.60 Intermediate level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A809V UL54 Foscarnet 4.40 Intermediate level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V812L UL54 Ganciclovir 2.50 Low level resistance Details A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. (Sep 1998)
    V812L UL54 Cidofovir 3.20 Intermediate level resistance Details A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. (Sep 1998)
    V812L UL54 Foscarnet 2.90 Low level resistance Details A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. (Sep 1998)
    V812L UL54 Brincidofovir 2.40 Low level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    T813S UL54 Ganciclovir 2.50 Low level resistance Details Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    T813S UL54 Cidofovir 2.90 Low level resistance Details Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    T813S UL54 Foscarnet 4.90 Intermediate level resistance Details Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    T821I UL54 Ganciclovir 4.50 Intermediate level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    T821I UL54 Cidofovir 1.90 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    T821I UL54 Foscarnet 21.00 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    G822D UL54 Non-viable Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V823A UL54 Cidofovir 3.60 Intermediate level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    V823A UL54 Foscarnet 0.50 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    V823A UL54 Ganciclovir 2.40 Low level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    M827I UL54 0.80 No resistance Details Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. (Jul 2016)
    M827I UL54 Cidofovir 0.70 No resistance Details Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. (Jul 2016)
    M827I UL54 Ganciclovir Natural polymorphism Details Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. (Jul 2016)
    M827I UL54 Foscarnet Natural polymorphism Details Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. (Jul 2016)
    M828V UL54 Non-viable Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P829S UL54 Ganciclovir 2.00 Low level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    P829S UL54 Cidofovir 1.60 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    P829S UL54 Foscarnet 1.10 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    A834P UL54 Ganciclovir 5.40 High level resistance Details Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. (Sep 2004)
    A834P UL54 Cidofovir 3.00 Intermediate level resistance Details Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. (Sep 2004)
    A834P UL54 Foscarnet 6.40 High level resistance Details Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. (Sep 2004)
    T838A UL54 Ganciclovir 1.80 No resistance Details How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    T838A UL54 Cidofovir 0.80 No resistance Details How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    T838A UL54 Foscarnet 2.40 Low level resistance Details How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    G841A UL54 Ganciclovir 3.20 Intermediate level resistance Details Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    G841A UL54 Cidofovir 2.60 Low level resistance Details Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    G841A UL54 Foscarnet 4.30 Intermediate level resistance Details Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    G841S UL54 Ganciclovir 2.20 Low level resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G841S UL54 Cidofovir 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G841S UL54 Foscarnet 2.10 Low level resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    M844T UL54 Ganciclovir 1.40 No resistance Details Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844T UL54 Cidofovir 1.30 No resistance Details Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844T UL54 Foscarnet 2.50 Low level resistance Details Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844V UL54 Ganciclovir 2.50 Low level resistance Details Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844V UL54 Cidofovir 1.60 No resistance Details Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844V UL54 Foscarnet 2.20 Low level resistance Details Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    R847H UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    N855D UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P859A UL54 Ganciclovir 0.80 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P859A UL54 Cidofovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P859A UL54 Foscarnet 0.80 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L862F UL54 Ganciclovir 1.70 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L862F UL54 Cidofovir 0.90 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L862F UL54 Foscarnet 1.10 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    H863R UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q868R UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    D870H UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    V873L UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G874R UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    in884T UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A885S UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A885T UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    in885S UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    in885T UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    P887S UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    L890S UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    L890F UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    T892I UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S897L UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    N898D UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    E899K UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    V902G UL54 Ganciclovir 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V902G UL54 Cidofovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V902G UL54 Foscarnet 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E903G UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G920S UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V927M UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A928T UL54 Ganciclovir >3.00 At least Intermediate level resistance Details Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    A928T UL54 Cidofovir >3.00 At least Intermediate level resistance Details Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    A928T UL54 Foscarnet >3.00 At least Intermediate level resistance Details Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    A928T UL54 Cidofovir 1.00 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A928T UL54 Foscarnet 0.90 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A928T UL54 Ganciclovir 0.90 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    S932N UL54 Natural polymorphism Details
    V946L UL54 Ganciclovir 1.10 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    V946L UL54 Cidofovir 0.90 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    V946L UL54 Foscarnet 2.40 Low level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    K947E UL54 Ganciclovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    K947E UL54 Cidofovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    K947E UL54 Foscarnet 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E949K UL54 Cidofovir 1.60 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949K UL54 Foscarnet 5.80 High level resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949K UL54 Ganciclovir 1.70 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949Q UL54 Cidofovir 1.70 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949Q UL54 Foscarnet 3.70 Intermediate level resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949Q UL54 Ganciclovir 1.40 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E951D UL54 Cidofovir 1.00 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D UL54 Cidofovir 1.20 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D UL54 Foscarnet 3.90 Intermediate level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D UL54 Foscarnet 4.40 Intermediate level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D UL54 Ganciclovir 2.20 Low level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D UL54 Ganciclovir 1.80 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V953A UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    R954H UL54 Natural polymorphism Details
    S956Y UL54 Natural polymorphism Details
    L957F UL54 Ganciclovir 2.70 Low level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L957F UL54 Cidofovir 1.40 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L957F UL54 Foscarnet 1.30 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    M959T UL54 Ganciclovir 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    M959T UL54 Cidofovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    M959T UL54 Foscarnet 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A972V UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    981-982del UL54 Ganciclovir 6.70 High level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    981-982del UL54 Cidofovir 4.20 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    981-982del UL54 Foscarnet 3.00 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    D981del UL54 Ganciclovir 8.30 High level resistance Details A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. (Dec 2000)
    D981del UL54 Cidofovir 2.80 Low level resistance Details A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. (Dec 2000)
    D981del UL54 Foscarnet 3.60 Intermediate level resistance Details A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. (Dec 2000)
    A987G UL54 Ganciclovir 5.30 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    A987G UL54 Cidofovir 11.30 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    A987V UL54 Cidofovir 0.90 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    A987G UL54 Foscarnet 1.20 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    A987G UL54 Cidofovir 8.50 High level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A987G UL54 Cidofovir 5.00 High level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A987V UL54 Foscarnet 3.10 Intermediate level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    A987V UL54 Ganciclovir 0.90 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    E989Q UL54 Natural polymorphism Details
    E989D UL54 Cidofovir 1.90 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    E989D UL54 Foscarnet 5.70 High level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    E989D UL54 Ganciclovir 3.20 Intermediate level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    G993C UL54 Natural polymorphism Details
    T995K UL54 Natural polymorphism Details
    N998D UL54 Natural polymorphism Details
    S1000L UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D1005N UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    R1006C UL54 Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    R1006G UL54 Natural polymorphism Details
    A1012V UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    L1020I UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    R1052C UL54 Natural polymorphism Details
    D1055L UL54 Natural polymorphism Details
    R1070G UL54 Natural polymorphism Details
    Q1071R UL54 Natural polymorphism Details
    L1074M UL54 Natural polymorphism Details
    V1079I UL54 Natural polymorphism Details
    T1108A UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    N1116H UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A1122T UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    P1129Q UL54 Natural polymorphism Details
    G1133S UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A1138T UL54 Natural polymorphism Details
    S1146N UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    N1147S UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    R1149T UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G1151del UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    P1153S UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    L1156del UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S1162L UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S1235T UL54 Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    C1241G UL54 Natural polymorphism Details
    D981del2 UL54 Cidofovir 3.70 Intermediate level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    D981del2 UL54 Foscarnet 3.10 Intermediate level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    D981del2 UL54 Ganciclovir 6.20 High level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    D981del2 UL54 Cidofovir 3.20 Intermediate level resistance Details Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    D981del2 UL54 Cidofovir 3.20 Intermediate level resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D981del2 UL54 Foscarnet 2.70 Low level resistance Details Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    D981del2 UL54 Foscarnet 3.00 Intermediate level resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D981del2 UL54 Ganciclovir 7.00 High level resistance Details Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    D981del2 UL54 Ganciclovir 7.50 High level resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E2K UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V12L UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    C25F UL56 Letermovir 5.40 High level resistance Details New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    V33A UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A36V UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    E75G UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    L122P UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    R129H UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A221V UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    S229F UL56 Letermovir 1.80 No resistance Details A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
    S229Y UL56 Letermovir 2.00 Low level resistance Details Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation. (Aug 2024)
    V231A UL56 Letermovir 2.10 Low level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    V231L UL56 Letermovir 5.00 High level resistance Details Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    V231L UL56 Letermovir 8.90 High level resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    V231L UL56 Letermovir 8.10 High level resistance Details Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation. (Aug 2024)
    N232Y UL56 Letermovir 17.00 High level resistance Details Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    Q234R UL56 Letermovir 2.00 Low level resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    V236A UL56 Letermovir 2.90 Low level resistance Details New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    V236L UL56 Letermovir 14.00 High level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    V236M UL56 Letermovir 45.00 High level resistance Details Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    V236M UL56 Maribavir 0.12 Possible hypersensitivity, no resistance Details Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. (Sep 2018)
    E237D UL56 Letermovir 10.00 High level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    L241P UL56 Letermovir 218.00 High level resistance Details Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    D242G UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    L243P UL56 Letermovir 1.00 No resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    T244K UL56 Letermovir 3.30 Intermediate level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    L254F UL56 Letermovir 3.20 Intermediate level resistance Details A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
    L257F UL56 Letermovir 8.60 High level resistance Details A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
    L257I UL56 Letermovir 4.90 Intermediate level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    K258E UL56 Letermovir 14.00 High level resistance Details Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    F261C UL56 Letermovir 4.40 Intermediate level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    F261L UL56 Letermovir 2.80 Low level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    S262C UL56 Letermovir 1.00 No resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    Y321C UL56 Letermovir 4.60 Intermediate level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    C325F UL56 Letermovir 3000.00 High level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    C325R UL56 Letermovir 3000.00 High level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    C325Y UL56 Letermovir 8796.00 High level resistance Details Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    C325W UL56 Letermovir 9300.00 High level resistance Details New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    A327V UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    L328V UL56 Letermovir 1.90 No resistance Details New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    L328I UL56 Letermovir 1.40 No resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    M329T UL56 Letermovir 4.40 Intermediate level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    M329I UL56 Letermovir 0.77 No resistance Details Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation. (Aug 2024)
    H335Y UL56 Letermovir 0.80 No resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    E339G UL56 Letermovir 1.20 No resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    F345L UL56 Letermovir 0.95-1.03 Range of values of No resistance Details Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    K350R UL56 Letermovir 1.10 No resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    V363I UL56 Letermovir 3.70 Intermediate level resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    A365S UL56 Letermovir 2.00 Low level resistance Details New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    N368D UL56 Letermovir 2.00 Low level resistance Details A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
    N368I UL56 Letermovir 1.30 No resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    R369T UL56 Letermovir 52.00 High level resistance Details Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients. (Mar 2020)
    R369G UL56 Letermovir 44.00 High level resistance Details Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    R369M UL56 Letermovir 13.00 High level resistance Details Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    R369S UL56 Letermovir 48.00 High level resistance Details Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    R369K UL56 Letermovir 4.90 Intermediate level resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    E393K UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    R396S UL56 Letermovir 81.00 High level resistance Details Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    T399I UL56 Letermovir 0.80 No resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    A425V UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    G436E UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    M442T UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A444G UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    S445N UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    N446del UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    N446S UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    449-451del UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    450-453del UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    T452I UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    S454N UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    G460V UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A464T UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A464V UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    V471A UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V476A UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    E485G UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    R507C UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    H509N UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    Q577R UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V582M UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    D586N UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A648R UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A648S UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    G649D UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    L658F UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    H698Q UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    C721Y UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    S749N UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V778A UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A779T UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A779V UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A788T UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    V793A UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V793P UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    P800L UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    P803A UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    Y806T UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    T811P UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A812E UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A812G UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    G813A UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A820Q UL56 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    L831M UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    G840A UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    S848N UL56 Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    T37A UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    L38M UL89 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    L89P UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    D94N UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    K95E UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    H216R UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    G239C UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    Q244H UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    Q249H UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    K253Q UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    K253T UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    E254A UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    R258P UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    A283P UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    N294D UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    N320H UL89 Letermovir 1.80 No resistance Details Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    N329S UL89 Letermovir 2.00 Low level resistance Details Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    D344E UL89 Letermovir 1.80 No resistance Details Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    D344E UL89 Maribavir 0.09 Possible hypersensitivity, no resistance Details Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. (Sep 2018)
    S345A UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    T350M UL89 Letermovir 2.80 Low level resistance Details Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    M359I UL89 Letermovir 1.50 No resistance Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    T448I UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    C511F UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    I531V UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    L548V UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    L562F UL89 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    G635S UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    A659V UL89 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A663V UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    D665E UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    A668P UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    F671S UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    R672K UL89 Natural polymorphism Details New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007)
    V673I UL89 Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    S7F UL97 Natural polymorphism Details Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    L14F UL97 Natural polymorphism Details Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    Q19E UL97 Natural polymorphism Details Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    Q54E UL97 Natural polymorphism Details
    N68D UL97 Natural polymorphism Details Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    N108S UL97 Natural polymorphism Details
    S108N UL97 Natural polymorphism Details Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    S108N UL97 Natural polymorphism Details Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. (Oct 2001)
    R112C UL97 Natural polymorphism Details A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. (Feb 2010)
    R112H UL97 Natural polymorphism Details Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    D118N UL97 Natural polymorphism Details
    L126Q UL97 Natural polymorphism Details Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    P132L UL97 Natural polymorphism Details Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    S133P UL97 Natural polymorphism Details Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    V171I UL97 Natural polymorphism Details Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    D184G UL97 Natural polymorphism Details
    G215A UL97 Natural polymorphism Details Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    A238T UL97 Natural polymorphism Details Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    I244V UL97 Natural polymorphism Details Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    P247S UL97 Natural polymorphism Details Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    S249C UL97 Natural polymorphism Details Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    F294C UL97 Natural polymorphism Details
    K316T UL97 Natural polymorphism Details
    E317A UL97 Natural polymorphism Details
    D329H UL97 Natural polymorphism Details Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002)
    Y335H UL97 Ganciclovir 0.90 No resistance Details Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    Y335H UL97 Maribavir 1.00 No resistance Details Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    L337M UL97 Maribavir 3.40 Intermediate level resistance Details Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. (Aug 2012)
    L337M UL97 Ganciclovir 1.02 No resistance Details Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. (Aug 2012)
    F342S UL97 Maribavir 18.00 High level resistance Details Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    F342S UL97 Ganciclovir 7.80 High level resistance Details Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    F342Y UL97 Maribavir 4.70 Intermediate level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    F342Y UL97 Ganciclovir 6.00 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    F342Y UL97 Ganciclovir 5.90 High level resistance Details Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    F342Y UL97 Maribavir 4.20 Intermediate level resistance Details Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    G343A UL97 Maribavir 126.00 High level resistance Details Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection. (Sep 2024)
    G343A UL97 Ganciclovir 8.50 High level resistance Details Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection. (Sep 2024)
    V345I UL97 Ganciclovir 1.30 No resistance Details Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    V345I UL97 Maribavir 0.40 Possible hypersensitivity, no resistance Details Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    L348V UL97 Ganciclovir 0.90 No resistance Details Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    L348V UL97 Maribavir 1.60 No resistance Details Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    V353A UL97 Maribavir 10.00 High level resistance Details Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. (Jul 2007)
    V353A UL97 Ganciclovir 1.00 No resistance Details Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. (Jul 2007)
    K355del UL97 Maribavir 304.00 High level resistance Details Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    K355del UL97 Ganciclovir 16.00 High level resistance Details Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    V356W UL97 Natural polymorphism Details
    V356L UL97 Natural polymorphism Details
    K356V UL97 Natural polymorphism Details
    V356G UL97 Maribavir 108.00 High level resistance Details Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    V356G UL97 Ganciclovir 5.50 High level resistance Details Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    K359E UL97 Ganciclovir 4.00 Intermediate level resistance Details Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. (Dec 2019)
    K359Q UL97 Ganciclovir 4.00 Intermediate level resistance Details Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. (Dec 2019)
    E362D UL97 Ganciclovir 3.80 Intermediate level resistance Details Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    E362D UL97 Maribavir 0.10 Possible hypersensitivity, no resistance Details Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    V388M UL97 Ganciclovir 1.20 No resistance Details Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    V388M UL97 Maribavir 1.10 No resistance Details Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    L397R UL97 Maribavir 390.00 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L397R UL97 Ganciclovir 2.30 Low level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L405P UL97 Ganciclovir 2.70 Low level resistance Details Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    T409M UL97 Maribavir 78.00 High level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    T409M UL97 Ganciclovir 1.30 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    T409M UL97 Maribavir 80.00 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    H411Y UL97 Maribavir 15.00 High level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    H411L UL97 Maribavir 21.00-99.00 Range of values of High level resistance Details Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
    H411L UL97 Ganciclovir 0.70 No resistance Details Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
    H411N UL97 Maribavir 9.00 High level resistance Details Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
    H411N UL97 Ganciclovir 0.71 No resistance Details Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
    H411Y UL97 Maribavir 17.00 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    H411Y UL97 Ganciclovir 0.50 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    H415Y UL97 Ganciclovir 1.10 No resistance Details Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    H415Y UL97 Maribavir 0.60 No resistance Details Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    A427V UL97 Ganciclovir 0.95 No resistance Details Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)
    T429I UL97 Natural polymorphism Details
    A435V UL97 Ganciclovir 1.00 No resistance Details Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    A435V UL97 Maribavir 0.60 No resistance Details Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    C437Y UL97 Ganciclovir 0.90 No resistance Details Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    C437Y UL97 Maribavir 0.90 No resistance Details Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    A440V UL97 Natural polymorphism Details Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis. (Dec 2010)
    A442G UL97 Natural polymorphism Details Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis. (Dec 2010)
    Q449K UL97 Details Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. (Oct 2001)
    Q449K UL97 Natural polymorphism Details Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. (Oct 2001)
    Q449R UL97 Natural polymorphism Details Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    D456N UL97 Maribavir 278.00 High level resistance Details Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    D456N UL97 Ganciclovir 12.00 High level resistance Details Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    M460L UL97 Natural polymorphism Details
    M460I UL97 Filociclovir 12.00 High level resistance Details Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. (Jan 2011)
    M460I UL97 Maribavir 0.21 Possible hypersensitivity, no resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    M460I UL97 Ganciclovir 12.00 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    M460T UL97 Ganciclovir 9.30 High level resistance Details Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    M460V UL97 Filociclovir 4.00 Intermediate level resistance Details Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. (Jan 2011)
    M460V UL97 Maribavir 0.30 Possible hypersensitivity, no resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    M460V UL97 Ganciclovir 9.10 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    V466M UL97 Maribavir Details
    V466G UL97 Maribavir 321.00 High level resistance Details Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    V466G UL97 Ganciclovir 11.00 High level resistance Details Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. (Apr 2010)
    V466M UL97 Ganciclovir 1.30 No resistance Details Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    H469Y UL97 Ganciclovir 1.00 No resistance Details Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    R476C UL97 Ganciclovir Details Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)
    A478V UL97 Ganciclovir 0.85 No resistance Details Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    C480F UL97 Ganciclovir 2.30 Low level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    C480F UL97 Maribavir 224.00 High level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    C480F UL97 Maribavir 210.00 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C480F UL97 Ganciclovir 2.30 Low level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C480R UL97 Maribavir 243.00 High level resistance Details Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    C480R UL97 Ganciclovir 9.00 High level resistance Details Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    N510S UL97 Ganciclovir 1.20 No resistance Details Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    C518Y UL97 Ganciclovir 12.00 High level resistance Details Rapid detection of human cytomegalovirus UL97 and UL54 mutations for antiviral resistance in clinical specimens. (May 2013)
    H520Q UL97 Filociclovir 5.00-20.00 Range of values of High level resistance Details Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. (Jan 2011)
    H520Q UL97 Maribavir 0.66 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    H520Q UL97 Ganciclovir 9.70 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    P521L UL97 Maribavir 428.00 High level resistance Details Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    P521L UL97 Ganciclovir 17.00 High level resistance Details Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    M550I UL97 Ganciclovir 0.85 No resistance Details Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)
    G561A UL97 Natural polymorphism Details Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    A582V UL97 Ganciclovir 0.82 No resistance Details Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)
    H587Y UL97 Ganciclovir Details
    H587Y UL97 Natural polymorphism Details Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    A588V UL97 Ganciclovir 1.15 No resistance Details Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    590-600del UL97 Ganciclovir 6.30 High level resistance Details Emergence of multiple human cytomegalovirus ganciclovir-resistant mutants with deletions and substitutions within the UL97 gene in a patient with severe combined immunodeficiency. (Feb 2001)
    590-603del UL97 Ganciclovir Details Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy. (Aug 1999)
    591-594del UL97 Ganciclovir 6.00 High level resistance Details A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. (Sep 1992)
    A591D UL97 Ganciclovir Details
    A591V UL97 Ganciclovir 1.30 No resistance Details Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. (Nov 2000)
    591-607del UL97 Ganciclovir 6.20 High level resistance Details Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002)
    C592G UL97 Ganciclovir 3.10 Intermediate level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    C592F UL97 Ganciclovir 31.50 High level resistance Details Aciclovir selects for ganciclovir-cross-resistance of human cytomegalovirus in vitro that is only in part explained by known mutations in the UL97 protein. (Sep 2001)
    C592G UL97 Filociclovir 2.20-4.90 Range of values between Low level resistance and Intermediate level resistance Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    C592G UL97 Maribavir 0.78 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C592G UL97 Ganciclovir 3.20 Intermediate level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C592G UL97 Ganciclovir 3.00 Intermediate level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    C592G UL97 Ganciclovir 3.10 Intermediate level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A594E UL97 Ganciclovir 3.00 Intermediate level resistance Details Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002)
    A594G UL97 Ganciclovir 13.50 High level resistance Details Value of a ligase chain reaction assay for detection of ganciclovir resistance-related mutation 594 in UL97 gene of human cytomegalovirus. (Sep 1997)
    A594P UL97 Ganciclovir 7.90 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    A594P UL97 Maribavir 1.60 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    A594S UL97 Ganciclovir 2.20-4.90 Range of values between Low level resistance and Intermediate level resistance Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    A594T UL97 Ganciclovir 5.00 High level resistance Details Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. (May 1997)
    A594T UL97 Maribavir 0.73 No resistance Details Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. (May 1997)
    A594V UL97 Filociclovir 2.20-4.90 Range of values between Low level resistance and Intermediate level resistance Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    A594V UL97 Maribavir 1.90 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    A594V UL97 Ganciclovir 6.90 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595F UL97 Maribavir 1.30 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595F UL97 Ganciclovir 6.20 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595S UL97 Filociclovir <2.20 No more than Low level resistance Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    L595S UL97 Maribavir 1.30 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595S UL97 Ganciclovir 7.50 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595W UL97 Maribavir 1.20 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595W UL97 Ganciclovir 9.00 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595del UL97 Ganciclovir 13.30 High level resistance Details A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. (Feb 1995)
    595-603del UL97 Ganciclovir 8.40 High level resistance Details Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy. (Mar 1999)
    E596Q UL97 Ganciclovir 2.70 Low level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    E596del UL97 Ganciclovir Details Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. ( 2009)
    E596G UL97 Ganciclovir 2.30 Low level resistance Details Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002)
    E596Y UL97 Ganciclovir 6.40 High level resistance Details Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients. ( 2015)
    N597del UL97 Ganciclovir Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    597-598del UL97 Ganciclovir Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    597-599del UL97 Ganciclovir Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    G598S UL97 Ganciclovir Details Emergence of a ganciclovir-resistant human cytomegalovirus strain with a new UL97 mutation in an AIDS patient. (May 1998)
    599-603del UL97 Ganciclovir 5.30 High level resistance Details Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant. (Dec 1998)
    K599E UL97 Ganciclovir Details Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. ( 2009)
    K599R UL97 Ganciclovir 1.10 No resistance Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    K599T UL97 Ganciclovir 5.30 High level resistance Details Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant. (Dec 1998)
    L600I UL97 Ganciclovir Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    L600del UL97 Ganciclovir 1.90 No resistance Details Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: The Cytomegalovirus and Viral Resistance Study Group Report Number 8. (Nov 2001)
    T601M UL97 Ganciclovir Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    601-602del UL97 Ganciclovir 11.00 High level resistance Details Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    601-603del UL97 Ganciclovir 11.00 High level resistance Details Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    C603R UL97 Ganciclovir Details Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. (Sep 2002)
    C603S UL97 Ganciclovir 1.90 No resistance Details Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. (Sep 2002)
    C603W UL97 Filociclovir 2.20-4.90 Range of values between Low level resistance and Intermediate level resistance Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    C603W UL97 Maribavir 1.20 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C603W UL97 Ganciclovir 5.90 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C603Y UL97 Maribavir 0.89 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C603Y UL97 Ganciclovir 2.80 Low level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    D605E UL97 Ganciclovir Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    C607F UL97 Ganciclovir 1.90 No resistance Details Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. (Dec 2001)
    C607Y UL97 Ganciclovir 12.50 High level resistance Details Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. (Dec 2001)
    I610T UL97 Ganciclovir 2.60 Low level resistance Details Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients. ( 2015)
    A613V UL97 Ganciclovir 2.30 Low level resistance Details Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation. (Dec 2013)
    M615V UL97 Natural polymorphism Details Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. (Jul 2011)
    Y617H UL97 Ganciclovir 0.84 No resistance Details Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)
    Y617del UL97 Maribavir 372.00 High level resistance Details Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    Y617del UL97 Ganciclovir 10.00 High level resistance Details Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    G623S UL97 Details
    A639T UL97 Natural polymorphism Details
    E655K UL97 Ganciclovir 1.70 No resistance Details Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. (Nov 2014)
    T659I UL97 Details
    T659I UL97 Ganciclovir 1.30 No resistance Details Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    V665I UL97 Details
    A669V UL97 Natural polymorphism Details
    A674T UL97 Ganciclovir 0.91 No resistance Details Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)

    Tilloy et al., 2024
    Interdeposit Digital Number: IDDN.FR.001.420004.000.S.X.2024.000.31230